Innovative therapeutics

Investors

Financial Statements

NASDAQBMRN
All numbers in thousands USD
Period Ending
Dec 31, 2017
Sep 30, 2017
Jun 30, 2017
Mar 31, 2017
Total Revenue
358,305
334,148
317,448
303,745
Cost of Revenue
75,995
59,480
56,305
50,006
Gross Profit
282,310
274,668
261,143
253,739
Operating Expenses
Research Development
168,608
154,103
143,039
145,003
Selling General and Administrative
160,280
130,532
143,505
120,019
Non Recurring
--
--
--
--
Others
20,375
3,760
13,411
8,925
Total Operating Expenses
349,263
288,395
299,955
273,947
Operating Income or Loss
(66,953)
(13,727)
(38,812)
(20,208)
Income from Continuing Operations
Total Other Income/Expenses Net
128,393
14
(7,523)
(4,751)
Earnings Before Interest And Taxes
62,537
(9,737)
(43,352)
(21,887)
Interest Expense
7,939
10,884
2,194
2,419
Income Before Tax
54,598
(20,621)
(45,546)
(24,306)
Income Tax Expense
105,990
(8,094)
(8,713)
(8,016)
Minority Interest
--
--
--
--
Net Income From Continuing Ops
(51,392)
(12,527)
(36,833)
(16,290)
Non-recurring Events
Discontinued Operations
--
--
--
--
Extraordinary Items
--
--
--
--
Effect Of Accounting Changes
--
--
--
--
Other Items
0
0
0
0
Net Income
(51,392)
(12,527)
(36,833)
(16,290)
Preferred Stock And Other Adjustments
--
--
--
--
Net Income Applicable To Common Shares
(51,392)
(12,527)
(36,833)
(16,290)

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Brineura™
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information